Jianfeng Group Lin2017 -023 (Announcement on the Company's Main Operating Data for the Half Year of 2017)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2017-023
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Main Operating Data of CompanyHalf Year The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
According to the relevant requirements of the "Guidelines for Industry Information Disclosure of Listed Companies No. 7-Pharmaceutical Manufacturing" and the "Notice on Doing a Good Job in Disclosure of Semi-annual Reports of Listed Companies in 2017 " issued by the Shanghai Stock Exchange, as the company is currently involved in the pharmaceutical manufacturing industry, the company's main operating data for the half year of 2017 are now disclosed as follows:
1. Reporting Period Business Data by Industry
Unit: RMB 10,000 Currency: RMB
Industry |
Main Business Income |
Main Business Cost |
Gross Profit Margin |
||||||
January-June 2017 |
January-June 2016 |
Growth Rate (%) |
January-June 2017 |
January-June 2016 |
Growth Rate (%) |
January-June 2017 (%) |
January-June 2016 (%) |
Increase or decrease percentage points |
|
Cement industry |
59,894.75 |
44,679.23 |
34.06 |
36,723.20 |
32,245.27 |
13.89 |
38.69 |
27.83 |
Increase 10.86 Percent |
Pharmaceutical Industry |
54,567.90 |
48,822.77 |
11.77 |
41,376.67 |
41,342.54 |
0.08 |
24.17 |
15.32 |
Increase 8.85 Percent |
Health Products Industry |
8,201.80 |
9,225.01 |
-11.09 |
5,619.83 |
6,578.37 |
-14.57 |
31.48 |
28.69 |
Increase 2.79 Percent |
Other Industries |
6,861.19 |
6,670.28 |
2.86 |
5,891.31 |
5,794.36 |
1.67 |
14.14 |
13.13 |
# Increase 1.01 percentage points |
total |
129,525.64 |
109,397.29 |
18.40 |
89,611. 01 |
85,960.54 |
4.25 |
30.82 |
21.42 |
Increase 9.40 Percent |
II, Sub-product Operating Data
Units in the Reporting Period: currency: RMB
Products |
Main Business Income |
Main Business Cost |
Gross Margin |
||||||
January-June 2017 |
January-June 2016 |
Growth Rate (%) |
January-June 2017 |
January-June 2016 |
Growth Rate (%) |
January-June 2017 (%) |
January-June 2016 (%) |
increase and decrease percentage points |
|
cement |
59,894.75 |
44,679.23 |
34.06 |
36,723.20 |
32,245.27 |
13.89 |
38.69 |
27.83 |
Increase 10.86 Percent |
Pharmaceutical Industry Products |
14,515.08 |
8,482.15 |
71.13 |
3,578.72 |
3,419.14 |
4.67 |
75.34 |
59.69 |
Increase 15.65 Percent |
Pharmaceutical Commercial Products |
40,052.82 |
40,340.62 |
-0.71 |
37,797.95 |
37,923.40 |
-0.33 |
5.63 |
5.99 |
Decrease 0.36 Percent |
Health Product |
8,201.80 |
9,225.01 |
|||||||
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page